Phase 1/1b Study of Oral PMD-026 in Patients With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer
Conditions: Metastatic Breast Cancer; Triple Negative Breast Cancer Intervention: Drug: PMD-026 Sponsor: Phoenix Molecular Designs Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials